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Cerebral hypoperfusion, or insufficient blood flow in the brain, occurs in many areas of the brain in patients diagnosed with autism 
spectrum disorder (ASD). Hypoperfusion was demonstrated in the brains of individuals with ASD when compared to normal healthy 
control brains either using positron emission tomography (PET) or single‑photon emission computed tomography (SPECT). The affected 
areas include, but are not limited to the: prefrontal, frontal, temporal, occipital, and parietal cortices; thalami; basal ganglia; cingulate 
cortex; caudate nucleus; the limbic system including the hippocampal area; putamen; substantia nigra; cerebellum; and associative 
cortices. Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an ASD were 
found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology 
in the brain. Evidence suggests that brain inflammation and vascular inflammation may explain a part of the hypoperfusion. There is 
also evidence of a lack of normal compensatory increase in blood flow when the subjects are challenged with a task. Some studies 
propose treatments that can address the hypoperfusion found among individuals diagnosed with an ASD, bringing symptom relief 
to some extent. This review will explore the evidence that indicates cerebral hypoperfusion in ASD, as well as the possible etiological 
aspects, complications, and treatments.
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INTRODUCTION
Autism spectrum disorder (ASD) is a complex neuro‑
developmental syndrome that begins before three years 
of age and is characterized by pervasive deficits in so‑
cial interaction, impairment in verbal and nonverbal 
communication, and stereotyped patterns of interests 
and activities (American Psychiatric Association 2013). 
Although there is no consensus on the cause of ASD, 
it is considered to involve multiple environmental and 
genetic risk factors (Al‑Ayadhi and Camel 2013, Saad et 
al. 2016). The interplay between genetic and environ‑
mental factors has become the subject of intensified 
research in the last several years (Coleman and Gilberg 
2011, Deth et al. 2008). 
Even though ASD is mainly diagnosed based on be‑
havioral criteria which identify alterations in social in‑
teraction, deficits in verbal and nonverbal receptive/
expressive behaviour and speech, typically including 
hyper‑focused repetitive behaviors (Raymond et al. 
2014), there is some evidence indicating that ASD is 
a medical disease involving multiple organs (Baumann 
2010, Bjørklund 2013, Geier et al. 2012, Kern et al. 2014, 
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Li et al. 2014). Some examples of health or medically 
related issues that appear to be a consistent part of 
the pathological picture in ASD include cerebral hy‑
poperfusion, oxidative stress, neuroinflammation, 
gastrointestinal inflammation and dysbiosis, immune 
dysregulation, mitochondrial dysfunction, and neu‑
rotransmitter abnormalities (El‑Ansary and Al‑Ayadhi 
2012, Essa et al. 2002). Moreover, many of these find‑
ings were correlated with core symptoms of ASD (Kern 
et al. 2012). 
In this review of the scientific literature up to date, 
the focus will be on cerebral hypoperfusion, or insuf‑
ficient blood flow in the brain, in patients with ASD. 
Evidence that indicates cerebral hypoperfusion in ASD 
will be discussed, as well as the possible etiological as‑
pects, complications, and treatments.
Evidence for cerebral hypoperfusion
Cerebral hypoperfusion has been demonstrated in 
ASD as compared to healthy controls in many parts of 
the brain, typically using positron emission tomogra‑
phy (PET) or single‑photon emission computed tomog‑
raphy (SPECT) (Boddaert and Zilbovicius 2002, Galuska 
et al. 2002, Sasaki 2015, Zilbovicius et al. 1995, 2000). 
Further scanning methods such as fMRI were also ad‑
opted in ASD neuro‑imaging with encouraging results 
(Dichter 2012, Jann et al. 2015, Philip et al. 2012). The 
hypoperfusion was detected on an individual basis in 
nearly 75% of the ASD children, with the current sen‑
sitivity of the imaging method (Zilbovicius et al. 2000). 
Furthermore, it has also been suggested that perfusion 
worsens with age in children diagnosed with ASD (Wil‑
cox et al. 2002); however, this latter finding is not con‑
sistent (Zilbovicius et al. 1995).
Studies using SPECT to examine perfusion in ASD
Most of the studies indicating cerebral hypoperfu‑
sion in ASD are conducted using SPECT. Some examples 
of studies that have found hypoperfusion in ASD using 
SPECT are as follows: Starkstein et al. (2000) compared 
30 patients diagnosed with ASD (11.1±7.0 years of age) 
and 14 patients (11.2±4.3 years of age) diagnosed with 
mental retardation, but no ASD, finding that patients 
diagnosed with ASD have significantly lower cerebral 
blood perfusion than the mentally retarded group in 
the right temporal lobe (basal and inferior areas), oc‑
cipital lobes, thalami, and left basal ganglia (Starkstein 
et al. 2000).
Wilcox et al. (2002) examined blood flow using 
SPECT in 14 individuals diagnosed with ASD and 14 
controls, ranging in age from 3 to 37 years and found 
significant hypoperfusion in the prefrontal areas of in‑
dividuals diagnosed with ASD as compared to controls. 
Sasaki et al. (2010) examined children, 4–16 years of 
age, diagnosed with both ASD and epilepsy. In all of the 
children, results showed a mixed hypoperfusion pat‑
tern, especially involving the prefrontal cortex, medial 
frontal cortex, anterior cingulate cortex, medial pari‑
etal cortex, and/or anterior temporal cortex.
Gupta and Ratnam (2009) assessed the cerebral 
perfusion in ten children diagnosed with ASD and 
mental retardation, 4–8 years of age, and found gen‑
eralized hypoperfusion in all ten cases as compared 
to age‑matched controls. Frontal and prefrontal re‑
gions revealed maximum hypoperfusion. Subcortical 
areas also indicated hypoperfusion. Ito et al. (2005) 
examined regional cerebral blood flow (rCBF) pattern 
in individuals diagnosed with high‑functioning ASD 
(9–14 years of age) and found significant hypoperfu‑
sion in the left temporal region compared to controls 
(7–15 years of age). 
Degirmenci et al. (2008) found that when compar‑
ing ten children diagnosed with ASD (6.9±1.7 years) 
with five age‑matched nonautistic children, statisti‑
cally significant hypoperfusion was found in the chil‑
dren diagnosed with an ASD in the right inferior and 
superior frontal, left superior frontal, right parietal, 
right mesial temporal and right caudate nucleus (De‑
girmenci et al. 2008). More recently, Yang et al. (2011) 
examined 23 children (7.2±3.0 years of age) diagnosed 
with an ASD and 8 age‑matched controls and found 
significant reduction in rCBF bilaterally in the fron‑
tal lobe (frontal poles, arcula frontal gyrus) and bi‑
laterally in basal ganglia in the ASD group, and in the 
Asperger syndrome group a decrease in the bilateral 
frontal, temporal, parietal lobes and also in cerebel‑
lum, compared to the perfusion in control children. In‑
terestingly, in the less affected children with Asperger 
syndrome, they found a pronounced asymmetry in the 
hemispheric hypoperfusion.
Also, using SPECT, Kaya et al. (2002) examined 
rCBF in 18 individuals diagnosed with ASD (mean age: 
6.13±1.99 years) and 11 nonautistic controls (mean 
age: 6.5±3.39 years) to determine the relationship 
between rCBF and the scores of the Ritvo‑Freeman 
Real Life Rating Scale, intelligence quotient (IQ) lev‑
els, and age. Hypoperfusion in rCBF in children diag‑
nosed with ASD, compared with the control group, was 
found in bilateral frontal, frontotemporal, temporal, 
and temporo‑occipital regions. However, they found 
no relationship between rCBF and the Ritvo‑Freeman 
Real Life Rating Scale. Burroni et al. (2008) examined 
rCBF in 11 children diagnosed with an ASD (mean age 
11.2 years) and eight age‑matched controls. There was 
a global reduction of cerebral blood flow (CBF) in the 
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children diagnosed with ASD when compared with the 
control group, and also a significant difference for the 
right‑to‑left asymmetry of hemispheric perfusion be‑
tween the two groups, with a right‑sided CBF‑reduction 
prevalence greater in children diagnosed with an ASD, 
as compared to the controls.
Mountz et al. (1995) studied rCBF in six individuals 
(mean age 13.7 years of age, ranging from 9 to 21 years 
of age) in reportedly severely affected individuals di‑
agnosed with ASD and age‑matched controls. The rCBF 
was abnormally low predominately in the temporal and 
parietal lobes, with the left cerebral hemisphere show‑
ing greater rCBF abnormalities than the right.
Ryu et al. (1999) studied 23 children aged 28–92 
months diagnosed with ASD, and they were found to 
have decreased perfusion in the cerebellar hemisphere, 
thalami, basal ganglia, and posterior parietal and tem‑
poral areas. Interestingly, even though the children had 
extensive perfusion impairments, the children’s mag‑
netic resonance imaging results were considered normal 
(Ryu et al. 1999).
George et al. (1992) scanned four young adults diag‑
nosed with ASD and four age‑matched controls. They 
stated that SPECT revealed not only a regional decrease 
in perfusion in ASD predominately in the right lateral 
temporal and right, left, and midfrontal lobes compared 
with controls, but also a decreased global perfusion 
ranging from 58% to 72% of controls.
Studies using PET to examine perfusion in ASD
PET, to a lesser extent than SPECT, has also been 
used to examine hypoperfusion in ASD. Examples of 
studies that have found hypoperfusion in individuals 
diagnosed with an ASD using PET are as follows: Zil‑
bovicius et al. (1995) examined rCBF in five children 
diagnosed with ASD at the age of 3–4 years and again 
three years later. They found frontal hypoperfusion in 
the children diagnosed with ASD at ages 3–4 years, but 
then three years later it had normalized by 6–7 years 
of age. Later, Zilbovicius et al. (2000) measured rCBF in 
21 children diagnosed with ASD (8–13 years of age) and 
in ten nonautistic children with idiopathic mental re‑
tardation and found highly significant hypoperfusion 
in both temporal lobes centered in associative auditory 
and adjacent multimodal cortex in the children diag‑
nosed with ASD. Brunelle et al. (2009) examined 77 chil‑
dren diagnosed with ASD and found reduced blood flow 
in the superior temporal sulcus of 21 of the children 
diagnosed with ASD along with the loss of grey matter. 
When these children were presented with sounds, there 
was no activation in the superior temporal sulcus, con‑
trary to normal children, signifying disruption in com‑
plex sensory inputs in the areas of hypoperfusion. 
Pagani et al. (2012) also using PET examined rCBF at 
rest in 13 adults diagnosed with ASD with normal intel‑
ligence (20–48 years of age) compared to ten IQ‑, sex‑ 
and age‑matched healthy controls (20–42 years of age). 
The adults diagnosed with ASD showed significant CBF 
increases in the right para‑hippocampal, posterior cin‑
gulate, primarily visual and temporal cortex, putamen, 
caudatus, substantia nigra and cerebellum as compared 
to controls (Pagani et al. 2012). However, no correlation 
between CBF and IQ was found. The limbic, posterior 
associative and cerebellar cortices showed increased 
blood flow in ASD.
Cerebral hypoperfusion associated 
with symptomatology in ASD
Studies indicate that not only rCBF is consistently 
decreased in ASD, but cerebral hypoperfusion is also 
related to symptomatology. Using SPECT on 23 chil‑
dren diagnosed with ASD with a mean age of 6.5 years 
(SD=2.4, range 2.6–13) and 26 non‑autistic age‑ and gen‑
der‑matched controls, Ohnishi et al. (2000) reported 
a correlation between syndrome scores and rCBF. Each 
syndrome was associated with a particular pattern of 
perfusion in the limbic system and the medial prefron‑
tal cortex. They stated that the perfusion abnormali‑
ties seemed to be related to the cognitive dysfunction 
observed in ASD, such as abnormal responses to senso‑
ry stimuli, and the obsessive desire for sameness. The 
perfusion patterns suggest possible locations of abnor‑
malities of brain function underlying abnormal behav‑
ior patterns in ASD individuals (Ohnishi et al. 2000). 
In another study using SPECT, mentioned earlier, 
Starkstein et al. (2000) found that decreased blood flow 
to the thalamus in patients diagnosed with an ASD was 
associated with repetitive, self‑stimulatory, unusual 
behaviors, a negative attitude towards changes in rou‑
tine and environment, and unusual sensory interests.
Furthermore, decreased IQ in individuals diagnosed 
with ASD has been associated with hypoperfusion of the 
temporal and frontal lobes (Hashimoto et al. 2000). Dif‑
ficulties in processing facial expressions and emotions 
were correlated with a decreased blood flow to the tem‑
poral lobes and amygdala (Critchley et al. 2000). Difficul‑
ties in recognizing familiar faces were correlated with 
a decreased blood flow to the fusiform gyrus (Pierce et 
al. 2004), and decreased blood flow to the Wernicke’s and 
Brodmann’s areas was correlated to impairments in lan‑
guage development and auditory processing (Boddaert 
and Zilbovicius 2002, Wilcox et al. 2002). 
A recent study by Jann et al. (2015) found frontotem‑
poral hyperperfusion and hypoperfusion in the dorsal 
anterior cingulate cortex in 17 children diagnosed with 
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ASD and 22 matched controls, and the decreased rCBF 
was accompanied by increased local functional con‑
nectivity in the anterior module of the default mode 
network (DMN). Both alterations were associated with 
greater social impairments. 
Gendry Meresse et al. (2005) investigated a putative 
relationship between rCBF of 45 children diagnosed with 
ASD measured at rest and their Autism Diagnostic Inter‑
view‑Revised (ADI‑R) scores. They found that a signifi‑
cant negative correlation appeared between reduced 
rCBF in the left superior temporal gyrus and the ADI‑R 
score. The more severe autism, the more decreased the 
rCBF in that region (Gendry Meresse et al. 2005).
Possible causes of the decreased rCBF in ASD
Although the origin of this lower baseline blood 
flow in the autistic brain is not entirely clear, several 
hypotheses can be formulated. For example, it is known 
that inflammation or swollen tissues lead to a gener‑
al increase in the pressure of the surrounding tissue, 
constricting blood vessels and ultimately impairing ir‑
rigation (cerebral hypoperfusion). Interestingly, exac‑
erbated inflammatory responses were extensively doc‑
umented in ASD patients, which could then be a pos‑
sible cause of the observed low baseline blood flow 
in the brain of patients with ASD (Morgan et al. 2010, 
Vargas et al. 2005). A recent evaluation of the research 
found evidence to suggest that a majority of children 
with ASD have an ongoing general neuro‑inflammation 
(Kern et al. 2015). 
Also, inflammation of the endothelial lining of the 
blood vessels in the brain of ASD‑patients has been re‑
ported. Several studies have shown vascular endotheli‑
um activation in children with ASD. Thus, upon using 
urinary levels of 6‑keto‑prostaglandin F1α as marker 
of endothelium activation, Yao et al. (2006) found that 
children with ASD had significantly higher urinary lev‑
els of this biomarker compared to controls, and ASD 
children were consequently presumed to suffer from 
some endothelial activation and/or dysfunction. Fur‑
thermore, lipid peroxidation levels directly correlated 
with the same vascular biomarker. The results of these 
investigators indicated increased oxidative stress, as 
well as platelet and vascular endothelial activation in 
the ASD patients (Yao et al. 2006).
Recent molecular research has identified genet‑
ic and epigenetic factors that can lead to, or contrib‑
ute to the development of ASD (Nguyen et al. 2010, 
Veenstra‑VanderWeele and Cook 2004). Sasaki (2015) 
reported that localized areas of hypoperfusion, e.g., in 
prefrontal lobes, cingulate gyrus, and temporal lobes, as 
identified by SPECT, could be caused by aberrant neuro‑
nal connectivity. The hypoperfusion could then reflect 
receptor, neurotransmitter or other neuronal defects 
(Homs et al. 2016, Huguet et al. 2013, Sasaki et al. 2015) 
which is analogues to the temporoparietal hypoperfu‑
sion observed on cerebral SPECT images of patients with 
Alzheimer’s disease (Jagust et al. 2001).
Although the aberrant perfusion reported in ASD 
patients in some cases may have a genetic origin, en‑
vironmental risk factors in ASD are important to con‑
sider, which has been pointed out by several investi‑
gators. For example, Olczak et al. (2000) reported that 
Thimerosal, an organomercurial additive used as pre‑
servative in some vaccines, represents a risk factor for 
ASD (Gallagher and Goodman 2010, Geier et al. 2014), as 
it could cause ischaemic degeneration of neurons in the 
prefrontal and temporal cortex, hippocampus, cerebel‑
lum, and pathological changes of the blood vessels in 
the temporal cortex in postnatally exposed rats. Other 
investigators have reported that mercury compounds 
are capable of altering vascular permeability, and thus 
these mercurials may be examples of environmental 
pollutants promoting the mechanisms leading to clini‑
cally recognizable ASD (Kempuraj et al. 2010). 
Evidence of a lack of the physiological 
compensatory increase in cerebral blood 
flow in ASD patients 
The brain is one of the most metabolically active 
organs, consuming about 20% of the available oxygen 
for normal functioning (Clarke and Sokoloff 1989). 
Therefore, a precise and timely regulation of the ox‑
ygen delivery (blood flow, perfusion, and hemoglo‑
bin affinity) is crucial for its optimal functioning and 
survival (Ballabh et al. 2004, Clarke and Sokoloff 1989, 
Hamel 2006). In a typical brain and under normal func‑
tioning, cerebral blood flow remains largely unchanged 
due to the basal tone of parenchymal arterioles and the 
contribution of large arteries to vascular resistance 
(Cipolla et al. 2009, Faraci and Heistad 1990). When the 
cerebral demands increase in an area (such as during 
engagement in an activity/task), vessels dilate in order 
to reduce resistance and increase blood flow to the area 
(Faraci and Heistad 1990). If blood flow does not in‑
crease to meet demand, an enhanced oxygen extraction 
from the blood might also aid to maintain oxygen de‑
livery (Iadecola 1998). Clinical symptoms of ischemia 
are, therefore, seen only after these two mechanisms 
have failed to meet the oxygen demands (Hossmann 
1994, Iadecola 1998). The mechanisms of auto‑regula‑
tion control of the cerebral blood flow are not yet fully 
understood, but most evidence points towards neuro‑
nal involvement (Busija and Hestad 1984). However, the 
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role of nitric oxide (NO), as well as other metabolic by‑
products in regulating blood flow, also suggest intrinsic 
innervation to play a role (Paulson et al. 1990, Talman 
and Nitschke‑Dragon 2007).
In ASD there appears to be a lack the normal com‑
pensatory increase in blood flow when engaged in 
a task, such as during speaking or focusing on solv‑
ing a problem (Allen and Courchesne 2003, Ohnishi et 
al. 2000). As shown by functional magnetic resonance 
imaging (fMRI) blood flow increases in the brain of 
normal children when they engage in a task that de‑
mands attention and sensory input. This physiological 
response appears to be absent in children diagnosed 
with ASD (Müller et al. 1999). A study has shown that 
neurologically healthy children present a drop in the 
resistance of the middle cerebral artery upon audito‑
ry stimulation, which indicates that the artery relaxes 
and blood flood flow increases, delivering more oxygen 
to this part of the brain. Conversely, upon the same 
stimulus, the resistance in the middle cerebral artery 
increased in children diagnosed with ASD, indicating 
that the artery contracts and thereby limits blood flow 
and oxygen delivery (Bruneau et al. 1992). The origin 
of this lack of the compensatory response (increased 
blood flow) upon a stimulus in the autistic brain is un‑
known, but it is likely to be related to an absence of the 
signal/receptor involved in vasodilatation in the brain 
(Ohnishi et al. 2000).
As mentioned, children diagnosed with ASD have 
abnormal rCBF in the bilateral insula, superior tempo‑
ral gyri and left prefrontal cortices (BA 9/45) compared 
with the non‑autistic controls. Ohnishi et al. (2000) 
suggested that these abnormal areas are related to the 
cognitive impairments observed in children diagnosed 
with ASD, such as deficits in language, impaired execu‑
tive function and abnormal responses to sensory stim‑
uli. Disturbance in the perception and modulation of 
sensory information is often observed in ASD patients. 
Several studies suggest that the insular cortex should 
be connected to a variety of paralimbic systems and 
heteromodal association areas that are important in 
processing complex sensory information (Augustine 
1996). Dysfunction in this area due to hypoperfusion 
could cause abnormal responses to sensory stimuli be‑
cause of the abnormal integration of sensory stimuli. 
Frontal and temporal abnormalities in ASD have also 
been demonstrated in EEG studies and other SPECT 
studies (Dawson et al. 1995, Mountz et al. 1995). 
Consequences of the hypoperfusion
It is well known that oxygen is crucial to life as it 
is involved in the generation of cellular energy (ATP) 
and therefore fueling all cellular functions. The mam‑
malian brain is in fact very sensitive to hypoxia, and 
it is one of the first organs to fail during oxygen lim‑
itations. Most of the deleterious processes under sub‑
oxic conditions are directly or indirectly triggered by 
the inability of the mammalian brain to maintain the 
required ATP levels (Allen and Courchesne 2003). In 
fact, several studies (Araghi‑Niknam and Fatemi 2003, 
Fatemi et al. 2001, Fatemi and Halt 2001, Nguyen et al. 
2010, Sheikh et al. 2010), have demonstrated a decrease 
in Bcl‑2 which is associated with increased apoptosis 
(cell death) in autistic brains (Shimizu et al. 1996). 
Therefore, proper brain oxygenation is a prerequisite 
not only for survival but also for optimum functioning. 
Thus, irrespective of the basic cause of the hypoperfu‑
sion in cerebral areas of ASD patients, the diminished 
blood flow indicates that oxygen limitations might be 
the explanation of at least some of the symptoms pres‑
ent in ASD patients (Ohnishi et al. 2000).
Furthermore, it has been shown that ASD patients 
have elevated levels of vascular endothelial growth 
factor (VEGF) in their cerebrospinal fluid. VEGF is 
produced by various cells under hypoxia, e.g., by vas‑
cular endothelial cells and macrophages (Brogi et al. 
1996, Namiki et al. 1995, Prandota 2010, Vargas et al. 
2005), indicating some degree of cerebral hypoxia in 
ASD patients. VEGF production might aim to improve 
diffusion of irrigation, as it was demonstrated that 
chronic exposure to VEGF leads to the appearance of 
small ‘holes’ within the endothelium, associated with 
improved microvascular permeability of vital substanc‑
es including NO and prostacyclin (Dobro gowska et al. 
1998, Murohara et al. 1998, Roberts and Palade 1995).
Possible treatments
Although there are no established treatments for hy‑
poperfusion in ASD, there are some studies and anecdotal 
reports of treatments that deserve a proper evaluation. 
Carnitine, for example (Hülsmann and Dubelaar 1992), 
a naturally occurring amino acid required for energy 
metabolism, may be useful. Vascular endothelial cells 
are more vulnerable to oxidative stress and are prone to 
lose carnitine early during hypoperfusion. In rats, L‑car‑
nitine supplementation reduced lipid peroxidation and 
oxidative DNA damage and enhanced oligodendrocyte 
marker expression and myelin sheath thickness in cases 
of chronic hypoperfusion (Ueno et al. 2015). Also, in hu‑
mans, carnitine administration was observed to increase 
significantly brain blood flow (Battistin et al. 1989, Posti‑
glione et al. 1992, 1999). The replenishment of the carni‑
tine that is reduced by hypoperfusion in ASD may be the 
reason for the reports of improved cognition in children 
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diagnosed with an ASD treated with carnitine (Fahmy et 
al. 2013, Geier et al. 2011).
Cilostazol, a quinolinone derivative medication that 
enhances the flow of blood and is used in the allevi‑
ation of the symptom of intermittent claudication in 
individuals, may also be helpful. Chronic hypoperfu‑
sion causes disintegration of white matter and is char‑
acterized by neuroinflammation, loss of oligodendro‑
cytes, and attenuation of myelin density (Choi et al. 
2016). However, in rats with chronic hypoperfusion, Ci‑
lostazol protected against white matter disintegration 
and cognitive impairments (Choi et al. 2016). Anecdotal 
reports suggest that children diagnosed with an ASD 
have improved cognition when treated with Cilostazol.
Although the results were mixed (Bent et al. 2012, Jep‑
son et al. 2011, Rossignol et al. 2007, 2012, Sampanthavi‑
vat et al. 2012), it has been suggested that hyperbaric oxy‑
gen therapy (HBOT) might be used to compensate for the 
decreased blood flow in ASD patients, by increasing the 
oxygen content of blood plasma and body tissues (El‑Baz 
et al. 2014). For example, Zádori et al. (2011) examined 
the survival and differentiation of neuroectodermal cells 
with stem cell properties at different oxygen levels and 
found that lesioned cortices under hypoxia (low oxygen 
levels) were partially corrected by HBOT. In a randomized 
study of 30 ASD children, Vecchione et al. (2016) report‑
ed significant improvements in visual perception, motor 
coordination, stereotypic behavior, hyperactivity, inap‑
propriate speech and general communication ability after 
repeated sessions of low‑pressure hyperbaric oxygen. 
Although long‑term use of the traditional antipsy‑
chotic agent Risperdal (risperidone) can have seri‑
ous side effects such as precipitation of a potentially 
permanent movement disorder (tardive dyskinesia), 
research suggests that it can reduce problematic be‑
haviors in autistic children (Kirino 2014) and improve 
brain perfusion. And risperidone has been reported 
to improve brain perfusion. Ozdemir et al. (2009) fol‑
lowed 11 ASD patients (6–7 years of age), who received 
risperidone therapy for three months. SPECT imaging 
demonstrated a relationship between clinical improve‑
ment and regional perfusion patterns after risperi‑
done treatment. However, considering that Risperdal 
(risperidone) has potentially fatal side effects, the risk 
to benefit ratio should be thoroughly evaluated before 
initiating this treatment.
Electro‑acupuncture also shows promise. Elec‑
tro‑acupuncture was evaluated in 55 children diagnosed 
with ASD using SPECT (Zhao et al. 2014). They found 
that after treatment, there were significant differenc‑
es in the ratios of rCBF and global CBF before and after 
treatment in the left and right prefrontal cortex, the 
left and right temporal lobe, and in the left Broca’s area. 
Also, the treated children exhibited symptomatic relief.
CONCLUSION
Cerebral hypoperfusion is consistently observed 
amongst individuals diagnosed with ASD, and evidence 
suggests that it plays an important role in the patho‑
physiology and that the hypoperfusion also reflects 
the autism severity. The basic cause of this hypoper‑
fusion may involve genetic, epigenetic, environmental 
or a composed set of factors. However, the evidence 
outlined in this review of the literature emphasized 
that hypoperfusion is a critical issue in ASD and that 
addressing this could represent important steps in at‑
tempts to arrest pathophysiological deterioration and 
also help to alleviate the symptomatology in individu‑
als diagnosed with ASD. 
A possible weak point of this study is the need to 
review the topic through a meta‑analysis investigation, 
in order to retrieve a wider and deeper focus on the is‑
sue. Actually, in a more general way, the best approach 
to show the significant hypo‑perfusion in autistic brain 
is to run a meta‑analysis on data from all published ar‑
ticles on that topic (Haidich 2010). In this sense, a me‑
ta‑analysis of the imaging in ASD is a next forthcoming 
target of the investigation. 
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